Belite Bio (BLTE) Income from Continuing Operations (2022 - 2026)
Belite Bio (BLTE) recorded quarterly Income from Continuing Operations of 26938000.0 in Q1 2026, up 99.89% quarter-over-quarter from 25324000000.0 in Q4 2025, and down 88.68% on a YoY basis from 237991228.96 in Q1 2025.
Belite Bio (BLTE) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Belite Bio's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 26938000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 88.68% year-over-year to 26938000.0; the TTM figure through Mar 2026 stood at 63360938000.0 (down 124.04% YoY), while the FY2025 annual figure was 75038000.0, down 107.61% from the prior year.
- Income from Continuing Operations was 26938000.0 for Q1 2026 at Belite Bio, up from 25324000000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 6783000.0 in Q4 2022 to a low of 25324000000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 7377433062.5 across 5 years, with a median of 6853500000.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations plunged 144392.13% in 2024, then jumped 99.82% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 6783000.0 in 2022, then declined by 3.05% to 6990000.0 in 2023, then slumped by 144392.13% to 10100000000.0 in 2024, then sank by 150.73% to 25324000000.0 in 2025, then jumped by 99.89% to 26938000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 26938000.0 (Q1 2026), 25324000000.0 (Q4 2025), and 21690000000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 727.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.94 Mn |
| Dec 31, 2025 | -25.32 Bn |
| Sep 30, 2025 | -21.69 Bn |
| Jun 30, 2025 | -16.32 Bn |
| Mar 31, 2025 | -14.28 Mn |
| Dec 31, 2024 | -10.10 Bn |
| Sep 30, 2024 | -8.67 Bn |
| Jun 30, 2024 | -9.49 Bn |
| Mar 31, 2024 | -7.87 Bn |
| Dec 31, 2023 | -6.99 Mn |
| Sep 30, 2023 | -10.94 Mn |
| Jun 30, 2023 | -6.81 Bn |
| Mar 31, 2023 | -6.90 Bn |
| Dec 31, 2022 | -6.78 Mn |
| Sep 30, 2022 | -2.40 Bn |
| Jun 30, 2022 | -2.39 Bn |